Niacin, a common form of vitamin B3, directly shut down the activity of DGAT2, an enzyme that drives triglyceride buildup in liver cells, according to laboratory and clinical research spanning cell cultures and human trials. In one clinical study, extended-release niacin at 2,000 mg per day produced a roughly 47 percent drop in liver fat measured by MRI in patients with high triglycerides. The findings point to a specific molecular target for a condition that affects a large share of adults worldwide and still lacks approved drugs aimed at this pathway.
Why blocking DGAT2 changes the calculus for fatty liver
Fatty liver disease progresses when liver cells accumulate excess triglycerides faster than they can export or burn them. DGAT2 sits at the final step of triglyceride assembly inside those cells, making it a bottleneck that, when blocked, can starve the fat-storage process at its source. Research in HepG2 human liver cells showed that niacin noncompetitively inhibits DGAT2 in a dose-dependent manner while leaving DGAT1 activity intact. That selectivity matters because DGAT1 and DGAT2 serve overlapping but distinct roles in lipid metabolism, and sparing DGAT1 may reduce the risk of off-target side effects.
Separate work from UT Southwestern Medical Center added a second layer to the mechanism. Researchers there found that DGAT2 inhibition blocks SREBP-1 activation, preventing the protein from migrating into the nucleus where it would otherwise switch on genes needed for new fat and triglyceride synthesis. In practical terms, shutting down DGAT2 does not just stop one batch of triglycerides from forming; it also dials back the genetic program that keeps producing the raw materials for future fat storage. That two-pronged effect helps explain why the liver-fat reductions seen in clinical testing have been so large.
One hypothesis that remains untested is whether genetic variation in DGAT2 could predict who benefits most from niacin. Specifically, patients carrying the DGAT2 rs10874540 minor allele might show at least 30 percent greater liver-fat reduction on 1,000 mg daily niacin than non-carriers under identical calorie-controlled diets over 12 weeks. No published trial has isolated that allele at that dose and duration, but the clinical data already hint at genetic influence on response, which makes this a testable and clinically relevant question.
Cell, clinical, and dietary evidence converge on niacin
The case for niacin as a DGAT2 inhibitor rests on three distinct lines of evidence. In cultured human hepatocytes, niacin reduced fat accumulation, lowered oxidative stress, and cut levels of the inflammatory cytokine IL-8, according to a study in Metabolism research. That same study reported reduced DGAT2 mRNA expression, suggesting niacin acts at both the protein-activity level and the gene-expression level.
The clinical trial published in PLoS ONE moved the question from petri dishes into people. In a cohort of hypertriglyceridemic patients given extended-release niacin titrated to 2,000 mg per day, MRI scans revealed a roughly 47 percent reduction in liver fat. The study also analyzed whether DGAT2 genetic polymorphisms modified the degree of response, providing early evidence that individual variation in the enzyme’s gene could influence treatment outcomes.
A third study approached the question from the dietary side. In a lifestyle-intervention cohort, higher habitual intake of niacin-rich foods predicted larger reductions in liver fat content over time. While dietary doses are far below the pharmacologic 2,000 mg used in the clinical trial, the directional consistency across cell, clinical, and observational data strengthens the overall signal that niacin exposure, at multiple levels, can influence liver fat storage.
Niacin itself is well characterized pharmacologically. It functions as a precursor to NAD and NADP, coenzymes involved in hundreds of metabolic reactions, and at pharmacologic doses its effects extend well beyond its basic vitamin role. Those higher doses bring familiar side effects, including flushing, pruritus, and potential elevations in liver enzymes, which must be weighed against any liver-fat benefit.
What the niacin–DGAT2 research still cannot answer
The strongest gap in the evidence is the absence of long-term liver histology data. The 47 percent fat reduction was measured by MRI, a sensitive tool for quantifying steatosis but not a direct readout of inflammation or fibrosis. Whether DGAT2 inhibition with niacin can reverse ballooning degeneration, lobular inflammation, or scar tissue remains unknown. For patients and clinicians, that distinction matters: lowering fat is encouraging, but regulatory agencies typically require histologic improvement or hard clinical outcomes before recognizing a therapy as disease-modifying.
Another unresolved issue is durability. The existing niacin trial followed patients for several months, not years. It is unclear whether DGAT2 inhibition continues to suppress liver fat over longer periods, or whether compensatory pathways in lipid metabolism eventually blunt the effect. Similarly, there are no data on what happens after niacin is stopped-does liver fat rebound quickly, slowly, or not at all if lifestyle changes are maintained?
Safety also deserves closer scrutiny in this specific context. Niacin has a long track record in dyslipidemia, but patients with fatty liver frequently have overlapping metabolic syndrome, insulin resistance, and varying degrees of liver impairment. It is not yet clear whether the risk–benefit balance of 2,000 mg extended-release niacin is the same in this population as it is in traditional lipid clinics. The potential for hepatotoxicity, especially when niacin is combined with other medications, underscores the need for careful dose selection and monitoring in future trials.
Finally, the genetic angle remains more suggestive than definitive. The PLoS ONE trial’s exploratory analyses of DGAT2 polymorphisms hinted that certain variants might predict a stronger or weaker MRI response, but the sample sizes were small and not powered for pharmacogenomic conclusions. To move from hypothesis to practice, larger trials will need to stratify patients by genotype from the outset and prespecify response thresholds that would make genotype-guided therapy clinically actionable.
How these findings could reshape fatty liver treatment
Despite the unanswered questions, the niacin–DGAT2 story is already shifting how researchers think about fatty liver disease. For years, treatment has focused on broad lifestyle advice and, in some cases, off-label use of insulin sensitizers or weight-loss drugs. A clearly defined enzymatic target that sits at the bottleneck of triglyceride synthesis offers a more precise lever. Even if niacin itself does not become the preferred therapy-because of side effects, dosing challenges, or competition from newer agents-its ability to inhibit DGAT2 in humans validates the pathway as druggable.
That validation is likely to accelerate efforts to develop more selective DGAT2 inhibitors, potentially with fewer systemic effects than high-dose niacin. At the same time, the dietary and genetic data suggest that a future care model might combine modest pharmacologic inhibition, personalized by genotype, with targeted nutritional strategies that support the same pathway. In such a model, niacin intake from food and supplements, DGAT2 sequence variants, and MRI-based fat measurements could all feed into a more tailored approach to preventing and treating fatty liver.
For now, niacin remains an intriguing but unproven option for directly attacking hepatic triglyceride synthesis. The convergence of mechanistic, cellular, clinical, and epidemiologic evidence around DGAT2 provides a coherent framework, but only larger, longer, and more granular trials-ideally with histologic endpoints and genetic stratification-will determine whether this decades-old vitamin can be repurposed as a modern, targeted therapy for fatty liver disease.
More from Morning Overview
*This article was researched with the help of AI, with human editors creating the final content.
